Precision Biosciences (DTIL) Return on Capital Employed (2019 - 2026)
Precision Biosciences (DTIL) posted quarterly Return on Capital Employed of 27.66% for Q1 2026, up 970.0% year-over-year from 2.59% in Q1 2025, and up 38.98% quarter-over-quarter from 45.33% in Q4 2025.
Precision Biosciences (DTIL) Return on Capital Employed (2019 - 2026) Analysis & Trends
Precision Biosciences (DTIL) has reported Return on Capital Employed for 8 consecutive years, with 27.66% the latest figure, recorded in Q1 2026.
- In Q1 2026, Return on Capital Employed rose 970.0% year-over-year to 27.66%; the TTM figure through Mar 2026 stood at 27.66% (up 970.0% YoY), while the FY2025 annual figure was 38.21%, down 1855.0% from the prior year.
- Return on Capital Employed grew to 27.66% in Q1 2026 per DTIL's latest filing, from 45.33% in the prior quarter.
- Across five years, Return on Capital Employed topped out at 5.13% in Q2 2024 and bottomed at 103.8% in Q3 2025.
- Historically, Return on Capital Employed has averaged 39.86% across 5 years, with a median of 37.36% in 2025.
- Annual changes were most pronounced in 2022 — Return on Capital Employed soared 4229 bps — and 2025, when it slumped 9282 bps.
- Precision Biosciences' Return on Capital Employed stood at 42.85% in 2022, then grew by 9 bps to 39.02% in 2023, then soared by 48 bps to 20.15% in 2024, then sank by 125 bps to 45.33% in 2025, then surged by 39 bps to 27.66% in 2026.
- Business Quant data shows DTIL's Return on Capital Employed at 27.66% in Q1 2026, 45.33% in Q4 2025, and 103.8% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 20.76% |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 10.74% |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -38.20% |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 13.68% |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 26.09% |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -6.85% |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -50.93% |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 7.88% |
| 10 | Precision Biosciences | 228.31 Mn | 140.77 Mn | - | -28.49% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -28.49% |
| Mar 31, 2026 | -27.66% |
| Dec 31, 2025 | -45.33% |
| Sep 30, 2025 | -103.80% |
| Jun 30, 2025 | -87.40% |
| Mar 31, 2025 | -37.36% |
| Dec 31, 2024 | -20.15% |
| Sep 30, 2024 | -10.98% |
| Jun 30, 2024 | -5.13% |
| Mar 31, 2024 | -24.88% |
| Dec 31, 2023 | -39.02% |
| Sep 30, 2023 | -33.46% |
| Jun 30, 2023 | -31.65% |
| Mar 31, 2023 | -39.94% |
| Dec 31, 2022 | -42.85% |
| Sep 30, 2022 | -45.81% |
| Jun 30, 2022 | -53.50% |
| Mar 31, 2022 | -28.67% |
| Dec 31, 2021 | -21.47% |
| Sep 30, 2021 | -16.72% |